Recent
Novo Nordisk acquires Akero Therapeutics in a $4.7 billion deal, strengthening its position in the expanding MASH market and planning new treatment synergies.
October 9, 2025
Source:
Novo Nordisk
Deal Value and Strategic Direction
Novo Nordisk has reached a definitive agreement to acquire Akero Therapeutics for an upfront payment of $4.7 billion, with additional milestone payments that could raise the total value to $5.2 billion (company press release). Shareholders will receive $54 per share in cash and up to $6 more per share if Akero’s leading drug candidate, efruxifermin (EFX), secures full US regulatory approval for compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH).
MASH Market Outlook
MASH, formerly called NASH, is a progressive liver disease closely linked to obesity and metabolic dysfunction. It's projected to impact up to 122 million US adults by 2050 (The Scientist).
The acquisition positions Novo Nordisk as a central player in MASH treatment, a field experiencing significant investment and competition.
Major competitors include Roche, which recently acquired 89bio for its FGF21 analog (Endpoints News).
Keep up with the story. Subscribe to the PR+ free daily newsletter
Source:
Akero Therapeutics
Pipeline Integration and Clinical Progress
Efruxifermin's Promise
Akero’s efruxifermin (EFX) stands out for its clinical results. The drug is currently in Phase 3 trials for moderate to advanced liver fibrosis and compensated cirrhosis linked to MASH. Notably, EFX demonstrated significant fibrosis regression in Phase 2 studies, including rare improvement in compensated cirrhosis patients (Akero press release).
Phase 2 data: 49% reduction in precirrhotic MASH, 29% in compensated cirrhosis (vs. 19% and 11% for placebo).
EFX is the only agent so far to show significant histological improvement in this advanced group.
Portfolio Synergy
Novo Nordisk plans to integrate EFX with its established metabolic disease drugs, such as semaglutide (Wegovy), which recently received FDA approval for MASH (FDA). Combination and sequencing approaches are actively being explored as potential next standards in metabolic liver disease therapy.
Read More
Source:
Getty Images
Regulatory, Financial, and Market Impact
Deal Terms and Board Approval
Per-share terms: $54 cash + $6 contingent value right (CVR).
Total upfront value: $4.7 billion; up to $5.2 billion with CVR milestone.
The transaction has unanimous board backing at Akero and is expected to close by year-end, pending regulatory approvals.
Competitive Landscape
The MASH treatment field is increasingly competitive. Roche’s acquisition of 89bio and advancing GLP-1 therapies—such as tirzepatide and semaglutide—raise the stakes for innovation (Fierce Biotech).
Financial Outlook
Novo Nordisk expects no impact on its 2025 operating profit but projects a negative free cash flow in 2025 of roughly $4 billion due to the deal.
What are the key benefits of Novo Nordisk acquiring Akero Therapeutics?
The acquisition strengthens Novo Nordisk's portfolio in metabolic and liver diseases, provides access to Akero’s innovative MASH drug EFX, and supports combination therapy strategies alongside existing drugs.
How does efruxifermin compare to other treatments for MASH?
What impact will this acquisition have on Novo Nordisk's existing products?
How does the acquisition affect the competitive landscape in the MASH treatment market?
What are the potential risks associated with this acquisition for Novo Nordisk?
Share this news:
